Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3 10 de July de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: Targeting SNORA38B attenuates tumorigenesis and sensitizes immune checkpoint blockade in non-small cell lung cancer by remodeling the tumor microenvironment via regulation of GAB2/AKT/mTOR signaling pathway 13 de May de 2024 by Journal for ImmunoTherapy of Cancer current issue
Response to: Correspondence on ‘Cardiovascular toxicities associated with bispecific T-cell engager therapy’ by Noguchi et al 22 de April de 2024 by Sayed, A., Munir, M., Poliner, M., Sughra, S., Epperla, N., Addison, D.
Correspondence on ‘Cardiovascular toxicities associated with bispecific T-cell engager therapy’ by Sayed et al 22 de April de 2024 by Noguchi, Y., Yan, M., Tachi, T., Yoshimura, T.
Correction: Poly-IC enhances the effectiveness of cancer immunotherapy by promoting T cell tumor infiltration 5 de April de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis 29 de March de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: SITC clinical Immuno-Oncology network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials 27 de March de 2024 by Journal for ImmunoTherapy of Cancer current issue
Correction: Targeting oxidative phosphorylation to increase the efficacy of immune-combination therapy in renal cell carcinoma 6 de March de 2024 by Journal for ImmunoTherapy of Cancer current issue
